GlobeNewswire

Constellation Brands to Present at Consumer Analyst Group of New York Conference, February 20, 2019

Share

VICTOR, N.Y., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that Bill Newlands, president and chief operating officer, and David Klein, chief financial officer, will present at the Consumer Analyst Group of New York (CAGNY) conference on Wednesday, February 20, 2019, at the Boca Raton Resort & Club in Florida. The presentation is scheduled to begin at 3:00 p.m. EST and is expected to cover the company’s strategic business activities, financial and operational performance, and outlook for the future.                    

A live audio webcast of the presentation can be accessed on the company’s website at www.cbrands.com by following the instructions in the “Investors” section under “Events & Presentations.” Following the presentation, the webcast will be available on the company’s website for replay through the close of business on Friday, March 29, 2019. Financial and statistical information discussed in the presentation and a reconciliation of any reported (GAAP) financial measures with comparable or non-GAAP financial measures will also be available on the company’s website in the “Investors” section under “Reporting.”

About Constellation Brands
Constellation Brands (NYSE: STZ and STZ.B), a Fortune 500® company, is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported brands such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. The company’s beer portfolio also includes Ballast Point, one of the most awarded craft brewers in the U.S., and Funky Buddha Brewery. In addition, Constellation is the world leader in premium wine, selling great brands that people love, including Robert Mondavi, Clos du Bois, Kim Crawford, Meiomi, Mark West, Black Box, Ruffino and The Prisoner. The company’s premium spirits brands include SVEDKA Vodka, Casa Noble Tequila and High West Whiskey.

Based in Victor, N.Y., the company believes that industry leadership involves a commitment to brand building, our trade partners, the environment, our investors and to consumers around the world who choose our products when celebrating big moments or enjoying quiet ones. Founded in 1945, Constellation has grown to become a significant player in the beverage alcohol industry with more than 100 brands in its portfolio; about 40 wineries, breweries and distilleries; and approximately 10,000 talented employees. We express our company vision: to elevate life with every glass raised.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

MEDIA CONTACTS INVESTOR RELATIONS CONTACTS
Mike McGrew 773-251-4934  |  Amy Martin 585-678-7141 Patty Yahn-Urlaub 585-678-7483  |  Bob Czudak 585-678-7170
  Tom Conaway 585-678-7503

A downloadable PDF copy of this news release enhanced with multimedia links can be found here: http://resource.globenewswire.com/Resource/Download/506da49a-1660-4b88-9568-dbd6afe5132d

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Vostok New Ventures depository receipt buy-back19.8.2019 08:00:00 CESTPress release

Stockholm, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Vostok New Ventures Ltd (“Vostok New Ventures” or “the Company”) has between August 14 and August 16, 2019 repurchased 32,400 ordinary Swedish Depository Receipts (SDRs), at an average price of SEK 60.90. This represents 0.04% of the total number of ordinary SDRs of Vostok New Ventures. The Company currently holds 7,640,503 repurchased ordinary SDRs. The total number of outstanding ordinary SDRs of Vostok New Ventures, excluding repurchased SDRs, is 78,194,806. For further information please contact: Björn von Sivers, Head of Investor Relations, Tel +46 8 545 015 50 Vostok New Ventures Ltd is an investment company with the business concept of using experience, expertise and a widespread network to identify and invest in assets with considerable potential for value appreciation. The company has a special focus on online marketplaces and businesses with strong network effects. The Swedish Depository Receipts (SDRs) of Vostok New Ventures are l

Vostok New Ventures återköper depåbevis19.8.2019 08:00:00 CESTPressemelding

Stockholm, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Vostok New Ventures Ltd ("Vostok New Ventures" eller "Bolaget") har mellan den 14 augusti och den 16 augusti 2019 återköpt 32 400 ordinarie depåbevis (SDB) i Bolaget till ett genomsnittligt pris om 60,90 SEK. Detta motsvarar 0,04% av det totala antalet ordinarie depåbevis i Vostok New Ventures. Bolaget innehar totalt 7 640 503 återköpta ordinarie depåbevis. Det totala antalet utestående ordinarie depåbevis i Vostok New Ventures, exklusive återköpta depåbevis, uppgår till 78 194 806. För ytterligare information, vänligen kontakta: Björn von Sivers, Investor Relations: +46 (0)8 545 015 50 Vostok New Ventures Ltd är ett investmentbolag vars affärsidé är att genom erfarenhet, kunskap och ett omfattande nätverk identifiera och investera i tillgångar med stor värdeökningspotential. Bolaget har ett särskilt fokus på digitala marknadsplatser och företag med starka nätverkseffekter. Vostok New Ventures depåbevis (SDB) är noterade på Nasdaq Stockholm,

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality16.8.2019 17:17:00 CESTPress release

Expanded TAVR Indication to Younger, More Active Patients Signals Groundbreaking Shift in the Future Treatment of Heart Valve Disease DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement (SAVR) and includes patients who may be younger and more active than higher-risk patients. The expanded indication approval is based on randomized clinical data from the global, prospective, multi-center Evolut Low Risk Trial, which evaluated three valve generations (CoreValve™, Evolut™ R, and Evolut™ PRO valves) in more than 1,400 patients. The data showed TAVR to have an excellent safety prof